retatrutide phase 2 trial obesity triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Looking forward to when #retatrutide's
Description
Why Choose New Wellness for Medical Weight Loss in San Antonio
The June 2023 publication in The New England Journal of Medicine described a study that found Retatrutide produced an average weight loss of about 24% after 48 weeks at the highest dose
You can compare and choose the best option for you
This is a big, expensive, almost two year trial
